HC Wainwright set a $4.00 target price on MannKind (NASDAQ:MNKD) in a research report report published on Wednesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other research firms have also recently weighed in on MNKD. BidaskClub upgraded MannKind from a sell rating to a hold rating in a research note on Friday, June 1st. ValuEngine raised MannKind from a sell rating to a hold rating in a research report on Saturday, June 2nd. Zacks Investment Research lowered MannKind from a buy rating to a hold rating in a research report on Wednesday, May 23rd. Finally, Maxim Group reaffirmed a sell rating on shares of MannKind in a research report on Friday, June 15th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $2.51.

MNKD stock opened at $1.78 on Wednesday. The company has a market cap of $312.10 million, a P/E ratio of -1.53 and a beta of 2.34. MannKind has a fifty-two week low of $0.98 and a fifty-two week high of $6.96. The company has a debt-to-equity ratio of -0.44, a current ratio of 0.48 and a quick ratio of 0.43.

MannKind (NASDAQ:MNKD) last posted its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.04. The business had revenue of $3.89 million for the quarter, compared to analysts’ expectations of $4.80 million. sell-side analysts anticipate that MannKind will post -0.76 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNKD. BlackRock Inc. increased its position in MannKind by 197.3% during the second quarter. BlackRock Inc. now owns 10,361,672 shares of the biopharmaceutical company’s stock worth $19,686,000 after buying an additional 6,876,144 shares during the period. Scopia Capital Management LP acquired a new position in MannKind during the first quarter worth approximately $2,575,000. Millennium Management LLC increased its position in MannKind by 544.7% during the first quarter. Millennium Management LLC now owns 1,039,696 shares of the biopharmaceutical company’s stock worth $2,371,000 after buying an additional 878,432 shares during the period. Schwab Charles Investment Management Inc. increased its position in MannKind by 181.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 698,982 shares of the biopharmaceutical company’s stock worth $1,329,000 after buying an additional 450,872 shares during the period. Finally, Bank of New York Mellon Corp increased its position in MannKind by 380.1% during the second quarter. Bank of New York Mellon Corp now owns 388,375 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 307,475 shares during the period. 25.44% of the stock is currently owned by institutional investors.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States.

See Also: Diversification

Receive News & Ratings for MannKind Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind and related companies with MarketBeat.com's FREE daily email newsletter.